Moderna (MRNA) is back in focus after its Q1 2026 earnings, reporting revenue of US$389 million compared with US$108 million ...

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports ...

Moderna Inc (MRNA) reports significant revenue growth and strategic advancements despite a substantial net loss due to litigation settlements.

By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for ...

Mock maintained cost targets and year-end liquidity outlook, stating, "we are expecting total GAAP operating expenses of $4.9 billion and cash costs of $4.2 billion" and "we expect to end 2026 with ...

Moderna (MRNA) beats 1Q26 revenue on international COVID sales, cuts costs, and eyes mRNA-1010 flu PDUFA Aug 5.

Moderna reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international ...

Moderna saw its first-quarter revenues nearly triple to $389 million compared to the same period of 2025, with international ...

By Blake Brittain April 24 (Reuters) - German biotech company CureVac sued Moderna in Delaware federal court on Friday, ...

Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.

This week, the European Commission authorized Moderna to market the vaccine, mRNA-1083 or mCOMBRIAX, making it the world’s ...

Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC ...